Mother-to-Child HIV Transmission: Risks and Reduction

When a mother living with HIV becomes pregnant, one of the most critical concerns is preventing transmission of the virus to her child. Mother-to-child transmission can occur during pregnancy, labor, delivery, or breastfeeding. Understanding the risks and how they can be reduced is essential for healthcare workers and families affected by HIV.

Understanding transmission rates without intervention 🔗

Without any medical intervention, the transmission rate from an HIV-positive mother to her child ranges from 15% to 45%. This wide range reflects differences in factors such as viral load, disease stage, and feeding practices. Before antiretroviral therapy became available, transmission rates were between 14% and 20% in European countries, and reached up to 43% in African countries.

The risk is not evenly distributed across the pregnancy and postpartum period. Transmission can happen at three distinct stages: during pregnancy as the virus crosses the placenta, during labor and delivery when the baby is exposed to maternal blood and vaginal fluids, and through breastfeeding when the virus is present in breast milk.

How breastfeeding affects transmission risk 🔗

Breastfeeding significantly increases the risk of HIV transmission when no preventive measures are in place. Research shows that breastfeeding transmission is estimated at around 16%, and prolonged breastfeeding can nearly double the overall infant HIV infection rate. Without treatment, approximately 20% of infants acquire HIV after two years of breastfeeding.

The duration of breastfeeding directly correlates with increased risk. Transmission can occur at any point during lactation, with the cumulative probability of infection rising as breastfeeding continues. Studies indicate that mixed feeding-combining breast milk with formula or other foods-carries higher transmission risks than exclusive breastfeeding.

Factors that increase transmission through breastfeeding 🔗

Several factors elevate the risk during breastfeeding. High maternal viral load in both blood and breast milk is strongly associated with increased transmission. Breast health issues such as mastitis, cracked nipples, or breast abscesses create additional pathways for the virus to reach the infant. Mothers with low CD4 counts face higher transmission risks, with one study showing transmission rates of 22% among mothers with CD4 counts below 500 cells/mL compared to just 2% for those with higher counts.

Women who acquire HIV during the breastfeeding period face especially high transmission risks because viral load peaks during primary infection. This highlights the importance of continued HIV prevention efforts for breastfeeding mothers.

The transformative impact of antiretroviral drugs 🔗

Antiretroviral therapy has revolutionized the prevention of mother-to-child transmission. When mothers take antiretrovirals during pregnancy and their infants receive prophylactic treatment, transmission rates drop dramatically. Countries with comprehensive ART programs have reduced transmission to 1-2%, compared to the 15-45% seen without intervention.

Lessons from the PETRA trial 🔗

The PETRA study, conducted in Tanzania, South Africa, and Uganda, was a landmark randomized controlled trial that examined different short-course regimens of zidovudine and lamivudine. The trial demonstrated that these antiretroviral combinations were effective in reducing HIV transmission at six weeks postpartum, though the benefits diminished after 18 months of follow-up.

This study was particularly important for resource-limited settings where full highly active antiretroviral therapy wasn’t widely accessible. It showed that even shorter, less expensive regimens could significantly reduce transmission during the critical peripartum period. However, the declining effectiveness over time underscored the need for sustained treatment throughout the breastfeeding period.

Current antiretroviral strategies 🔗

Today’s prevention strategies center on lifelong ART for all pregnant women living with HIV, regardless of CD4 count. Studies show transmission rates as low as 0.3% at six months and 0.6% at 12 months when mothers receive ART throughout pregnancy and breastfeeding. The most effective approach involves starting treatment before conception, maintaining viral suppression throughout pregnancy, and continuing therapy while breastfeeding.

Infant prophylaxis also plays a crucial role. Newborns receive antiretroviral medications for several weeks after birth to provide additional protection. Research comparing maternal ART to infant antiretroviral prophylaxis shows both approaches effectively reduce transmission during breastfeeding.

Comparing outcomes between developed and developing nations 🔗

The stark contrast in mother-to-child transmission rates between high-income and low-income countries reflects differences in healthcare infrastructure, access to treatment, and continuity of care.

Success in developed countries 🔗

In resource-rich countries, comprehensive prevention programs have achieved remarkable results. The United Kingdom and France have reduced transmission rates to 0.3% and 0.2% respectively. These countries benefit from early HIV testing, immediate access to antiretroviral therapy, regular viral load monitoring, and alternatives to breastfeeding when safe formula feeding is available.

The healthcare systems in developed nations support pregnant women through every step of the prevention cascade-from initial HIV testing to postpartum care. Women typically start ART early in pregnancy or even before conception, allowing time to achieve viral suppression before delivery.

Challenges in resource-limited settings 🔗

The situation differs significantly in many developing countries. In a 2019 survey of 21 sub-Saharan African countries, transmission rates varied from 2% to 25%. Countries like Botswana, Eswatini, South Africa, and Namibia achieved rates below 5%, while others faced much higher rates due to limited healthcare access.

Multiple barriers contribute to higher transmission rates in resource-limited settings. Many women receive their first antenatal care late in pregnancy, reducing the time available for viral suppression before delivery. Healthcare infrastructure challenges affect medication supply chains and laboratory capacity for viral load monitoring. Cultural practices around infant feeding can conflict with medical recommendations. Additionally, maternal adherence to treatment is complicated by poverty, stigma, and competing daily survival needs.

The retention in care challenge 🔗

A critical issue affecting transmission rates globally is retention in care. Nearly 65% of new HIV infections among children in 2024 occurred because mothers either didn’t receive ART or discontinued treatment during pregnancy or breastfeeding. Even when initial ART coverage appears high, many women drop out of care after being initially counted as receiving treatment.

Poor service delivery in the postpartum period, populations living in hard-to-reach areas, weak health systems, and persistent stigma all discourage women from seeking and maintaining care. These systemic failures disproportionately affect women in developing nations.

Progress and remaining gaps 🔗

Global efforts have made substantial progress in reducing mother-to-child transmission. Between 2000 and 2024, approximately 4.4 million children were prevented from acquiring HIV through prevention programs. New infections among children dropped from 310,000 in 2010 to 120,000 in 2024-a 62% decline.

However, this progress falls short of global elimination targets. The global mother-to-child transmission rate dropped from 23% in 2010 to 10% in 2024, but remains well above the 5% elimination threshold for breastfeeding countries and the 2% threshold for non-breastfeeding countries.

Achieving virtual elimination requires addressing the social determinants that prevent women from accessing and staying in care. This includes strengthening health systems, reducing stigma, supporting women economically, and integrating prevention services into broader maternal and child health programs.

What do you think? How can healthcare systems better support pregnant women living with HIV to remain in care throughout pregnancy and breastfeeding? What role should community programs play in reducing stigma and improving access to prevention services?

References

1. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv
2. https://www.aidsmap.com/about-hiv/how-likely-mother-child-transmission-hiv
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3382106/
4. https://www.scielo.br/j/rimtsp/a/3qC7ThVBJpCF7jmWsTp67zk/
5. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/preventing-transmission-infant-feeding
6. https://data.unicef.org/topic/hivaids/emtct/